About the Company
cullinan oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. sourced from the cullinan dry lab as well as external collaborators, cullinan’s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
73
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $CGEM News
Cullinan Oncology Inc (CGEM) Reports Fourth Quarter and Full Year 2023 Financial Results
Increased to $34.8 million in Q4 2023 from $33.8 million in Q3 2023, primarily due to increased clinical costs. G&A Expenses: Decreased to $10.6 million in Q4 2023 from $11.0 million in Q3 2023, ...
Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation
But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. So, the natural question for Cullinan Oncology (NASDAQ:CGEM) shareholders is whether they ...
CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q4 2023
Cullinan Oncology (NASDAQ:CGEM) just reported results for the fourth quarter of 2023. Cullinan Oncology reported earnings per share of -54 cents. This was above the analyst estimate for EPS of -96 ...
Cullinan Oncology: Q4 Earnings Insights
Cullinan Oncology CGEM reported its Q4 earnings results on Thursday, March 14, 2024 at 07:00 AM. Here's what investors need to know about the announcement. Cullinan Oncology beat estimated earnings by ...
Harbour BioMed Reports Full Year 2023 Financial Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, March 28, 2024 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the ...
Stocks Gain as U.S. Unemployment Report Bolsters the Outlook for Fed Rate Cuts
Aldeyra Therapeutics Inc (ALDX), ALX Oncology Holdings Inc (ALXO ... (CRBU), Comtech Telecommunications Cor (CMTL), Consumer Portfolio Services In (CPSS), Cullinan Oncology Inc (CGEM), Eve Holding Inc ...
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Cullinan remains on track to report additional solid tumor dose escalation data for CLN-619 in the second quarter of 2024 and recently received FDA clearance for an IND to evaluat ...
Loading the latest forecasts...